Pacific GeneTech (“PGT”) is an international early to mid-stage biotech company formed in 2009 to research, develop and commercialize a range of vaccines and related technologies that combat emerging infectious diseases caused by viruses, bacteria and parasites. PGT’s vaccines are based on a novel and potentially disruptive vaccine technology platform called “Isis” for which PGT has an exclusive global license. In addition, PGT has an adjuvant technology portfolio including an exclusive global license for a proprietary adjuvant “Hercules” that has proven to have excellent immune enhancement characteristics. The company has revenue producing out-licenses with two multi-national companies that are currently filing for regulatory approvals for two Isis candidates.
Raising US$ 10 mm – Convertible preferred stock (“Series D”)
Featured Presenter: Mr. Tim Collard, CEO Pacific GeneTech
Below firm & detail.
Introduction
Pacific GeneTech (“PGT”) is an international early to mid-stage biotech company formed in 2009 to research, develop and commercialize a range of vaccines and related technologies that combat emerging infectious diseases caused by viruses, bacteria and parasites. PGT’s vaccines are based on a novel and potentially disruptive vaccine technology platform called “Isis” for which PGT has an exclusive global license. In addition, PGT has an adjuvant technology portfolio including an exclusive global license for a proprietary adjuvant “Hercules” that has proven to have excellent immune enhancement characteristics. The company has revenue producing out-licenses with two multi-national companies that are currently filing for regulatory approvals for two Isis candidates.
Commercial Development
In 2011, PGT entered into a license agreement with a major multinational pharmaceutical company’s animal health division for vaccines that address multiple food safety pathogens for use across several animal species including poultry, ruminants and swine. The initial vaccine candidates under this agreement are moving toward product registration. In 2012 PGT entered into a second license agreement with a second major multinational animal health company for a vaccine technology targeting Eimeria, which is expected to be available in the market in 2015.
Development of further vaccine candidates addressing other unmet needs in animal health is underway and the subject of discussions with potential licensees. Development of Isis continues through sponsored research agreements with the research institutions to include other applications for animals and humans.
Revenue Generating
PGT currently generates fee revenue through its licensing agreements. The revenues are material to the company’s overall costs including its operating costs, R&D expenditures and intellectual property costs. The licensing revenues are expected to continue and PGT expects to realize royalty revenue when its first products are available in the market in 2015.
Corporate Strategy
PGT’s business strategy is built around a focus on three primary activities:
– undertaking discovery R&D in collaboration with leading research institutions on vaccine technologies that represent solid commercial opportunities to satisfy unmet needs;
– developing and executing the optimum strategies for exploiting each of the commercial opportunities through the best partnerships and collaborations for each opportunity;
– capturing and enhancing valuable IP that arises from the R&D collaborations to broaden the applications of that IP to generate additional products.
Organization
PGT is led by Mr. Tim Collard, CEO, an industry professional with 35 years of experience and related scientific credentials. The Chairman of the Board is Mr. Louis Bowen, Co-founder of PGT and a financial professional with 40 years of experience including overseeing other health care investments. PGT’s Director of Business Development is Ms. Cindy Tsang with over 10 years of experience in pharmaceutical research and business / investment experience in healthcare with a life sciences degree and an MBA.
PGT’s Scientific Advisory Board includes Dr. Billy Hargis, the Director of the Poultry Health Lab at the University of Arkansas and the Principal Investigator for Isis. Also, Dr. Anna Obolensky is a Scientific Advisor for human vaccine applications. In addition, Dr. Luc Berghman, who is a co-inventor in the Isis platform, works closely with Dr. Hargis in PGT research projects. PGT’s group headquarters is located in Hong Kong with a subsidiary in Arkansas, USA.
RSVP deadline is past